Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...
Some of the biggest highlights from obesity studies in 2024 included new data on semaglutide and tirzepatide, as well as a new study on risks with sarcopenia. Image: Adobe Stock SURMOUNT-OSA ...
The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...
Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
News Medical on MSN7d
Why do people with obesity, but without diabetes, start taking semaglutide?Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
This repeated cross-sectional study including 69.2 million obesity management drug dispensed prescriptions revealed an increase from 0.76 million in July 2017 to 1.5 million in February 2024, with an ...
Under NICE recommendations, tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity, in adults, with a BMI of at ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
1d
Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Palatin Technologies (PTN – Research Report), retaining the price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback